Heme-Binding Agents for Extravasation Damage Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for radiation exposure fail to effectively address the damage caused by break-down products of blood cells that leak into the extravascular space, leading to increased morbidity and mortality, and may result in long-term medical problems or side effects.
Innovation Solution
Administration of submicron protein particles or heme-binding agents, which can be given orally, intramuscularly, subcutaneously, intraperitoneally, or intravenously, to mitigate the harmful effects of break-down products such as hemoglobin and other toxic molecules in the extravascular compartment, reducing the need for blood transfusions and minimizing mortality and morbidity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If blood component transfusions are administered to irradiated patients, then morbidity and mortality are decreased, but the presence of break-down products from blood cells in the extravascular space causes detrimental inflammatory responses
Solution Approach 1:
The patent applies this principle by using heme-binding agents to convert the harmful effect of free heme (which causes inflammation) into a beneficial outcome. The agents bind free heme in the extravascular space, preventing its harmful inflammatory effects while allowing the beneficial aspects of blood transfusion to proceed. This transforms the toxic byproduct into a controlled interaction that protects against harm.
Solution Approach 2:
The patent extracts and removes the harmful component (free heme) from the system by introducing heme-binding agents that specifically bind and sequester free heme in the extravascular space. This separation allows the beneficial blood components to remain functional while the toxic heme is removed from circulation and neutralized.
2Adaptability or versatility
If anti-platelet or anti-coagulation treatment is administered, then patients can receive necessary medical therapy, but excessive internal bleeding occurs leading to increased morbidity and mortality
Solution Approach 1:
The patent introduces heme-binding agents as intermediary substances that mediate between the need for anti-coagulation therapy and the risk of excessive bleeding. These agents bind free heme released from extravasated blood cells, preventing the inflammatory cascade that would otherwise be triggered by heme, thereby allowing anti-coagulation therapy to proceed safely.
3Reliability
If current radiation sickness treatments are used, then some protection is provided, but the break-down products of blood cells in the extravascular compartment are not addressed
Solution Approach 1:
The patent specifically targets and extracts the overlooked harmful factor (free heme and other break-down products) from the extravascular space using heme-binding agents. This addresses the gap in current treatments by removing the specific toxic components that existing therapies fail to address.
Solution Approach 2:
The patent converts the previously neglected harmful break-down products into a manageable situation by using heme-binding agents to bind free heme, transforming it from a toxic substance into a controlled complex that can be safely processed and eliminated by the body's natural systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The treatment significantly reduces morbidity and mortality by effectively removing or binding harmful break-down products, potentially eliminating the need for blood component transfusions and minimizing long-term medical issues in irradiated patients or those with leaky endothelium.
Implementation Method 1
administration of agents that can bind or mitigate the effects of the break-down products of blood cells that have leaked into the extravascular space
Data Source
AI summary
A method of treating a patient who has extravasation of blood from an intravascular compartment to an extravascular compartment. An agent is administered to the patient which mitigates a harmful effect of break-down products of blood at an extravascular site, resulting in the patient having reduced morbidity and mortality. The morbidity and mortality of the patient is further reduced by concomitant administration of a suspension of submicron protein spheres having a molecular weight of ranging from 780 billion Daltons to less than 0.8 billion Daltons.